Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement

Affiliations

• ¹ Prenatal Cell and Gene Therapy Group, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London WC1E 6HX, UK.
• ² Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston- Salem, NC 27101, USA.
• ³ Division of Maternal-Fetal Medicine, John's Hopkins, Baltimore, MD 21218, USA.
• ⁴ KK Women's and Children's Hospital, Duke-NUS Medical School, Singapore 229899, Singapore.
• ⁵ Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
• ⁶ Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, ANA Futura, Karolinska Institutet, 141 52 Huddinge, Sweden.
• ⁷ EspeRare Foundation, Avenue de Secheron 15, Geneva 1202, Switzerland.
• ⁸ Department of Surgery and the Center for Maternal-Fetal Precision Medicine, University of California, San Francisco, San Francisco, CA, USA.
• ⁹ Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
• ¹⁰ Department of Paediatrics and Center for Ectodermal Dysplasias, University Hospital Erlangen, Erlangen, Germany.
• ¹¹ Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital, Taipei, Taiwan.
• ¹² Prenatal Cell and Gene Therapy Group, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London WC1E 6HX, UK; Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
• ¹³ Prenatal Cell and Gene Therapy Group, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London WC1E 6HX, UK; NIHR University College London Hospitals Biomedical Research Centre, 149 Tottenham Court Road, London W1T 7DN, UK; Department of Development and Regeneration, Katholieke Universiteit, Leuven, Belgium. Electronic address: [email protected].